mRNA pancreatic cancer vaccine trial shows promising results in phase I study

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Results from a phase I trial at Memorial Sloan Kettering Cancer Center suggest that treatment with mRNA vaccines (autogene cevumeran) cause an effective and lasting immune response in some patients with pancreatic cancer. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

If you believe in the miraculous healing power of ivermectin, hydroxychloroquine, and the harm from vaccination for HPV and COVID-19, you’ve got a powerful friend in Sen. Ron Johnson (R-WI), chair of the Permanent Subcommittee on Investigations of the Senate Committee on Homeland Security and Governmental Affairs.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login